✦ LIBER ✦
Otelixizumab – dose regimen optimization of a chimeric/humanized aglycosylated anti-CD3 monoclonal antibody (MAb) in adult subjects with type 1 diabetes mellitus (T1DM)
✍ Scribed by Rosenzweig, M.; Mehta, D.; Forman, D.; McKee, C.; Vaickus, L.
- Book ID
- 122054073
- Publisher
- Canadian Diabetes Association
- Year
- 2009
- Tongue
- English
- Weight
- 436 KB
- Volume
- 33
- Category
- Article
- ISSN
- 1499-2671
No coin nor oath required. For personal study only.